94.6%
nivolumabsolitomabrelatlimabA375 melanomaNEJM
…he combination strategy of relatlimab (anti-LAG-3 antibody) and nivolumab (anti-PD-1 antibody) approved at the beginning of 2024 as a fir…
1articles mentioning drugs
3drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: solitomab ×
solitomab
This drug is selected. Its supporting articles are shown below.